TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. - Archive ouverte HAL Access content directly
Journal Articles Journal of Pharmacology and Experimental Therapeutics Year : 2010

TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition.

(1) , (2) , (3) , (2) , (1) , (1) , (4) , (4) , (1) , (1) , (2) , (3) , (2) , (1, 2)
1
2
3
4

Abstract

3,5-Seco-4-nor-cholestan-5-one oxime-3-ol (TRO40303) is a new cardioprotective compound coming from a chemical series identified initially for neuroprotective properties. TRO40303 binds specifically to the mitochondrial translocator protein 18 kDa (TSPO) at the cholesterol site. After intravenous administration, TRO40303 tissue distribution was comparable to that of TSPO, and, in particular, the drug accumulated rapidly in the heart. In a model of 35 min of myocardial ischemia/24 h of reperfusion in rats, TRO40303 (2.5 mg/kg) reduced infarct size by 38% (p < 0.01 versus control), when administered 10 min before reperfusion, which was correlated with reduced release of apoptosis-inducing factor from mitochondria to the cytoplasm in the ischemic area at risk. Although TRO40303 had no effect on the calcium retention capacity of isolated mitochondria, unlike cyclosporine A, the drug delayed mitochondrial permeability transition pore (mPTP) opening and cell death in isolated adult rat cardiomyocytes subjected to 2 h of hypoxia followed by 2 h of reoxygenation and inhibited mPTP opening in neonatal rat cardiomyocytes treated with hydrogen peroxide. The effects of TRO40303 on mPTP in cell models of oxidative stress are correlated with a significant reduction in reactive oxygen species production and subsequent calcium overload. TRO40303 is a new mitochondrial-targeted drug and inhibits mPTP triggered by oxidative stress. Its mode of action differs from that of other mPTP inhibitors such as cyclosporine A, thus providing a new pharmacological approach to study mPTP regulation. Its efficacy in an animal model of myocardial infarctions makes TRO40303 a promising new drug for the reduction of cardiac ischemia-reperfusion injury.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-00497589 , version 1 (05-07-2010)

Identifiers

Cite

Sophie Schaller, Stéphanie Paradis, Gladys A. Ngoh, Rana Assaly, Bruno Buisson, et al.. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition.. Journal of Pharmacology and Experimental Therapeutics, 2010, 333 (3), pp.696-706. ⟨10.1124/jpet.110.167486⟩. ⟨inserm-00497589⟩
460 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More